SCHEMBL24462010

SCHEMBL24462010

N=C(Nc1cccc(F)c1)SCc1ccc(C(F)(F)F)cc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MTOR P42345 2/20 0.56
MAOB P27338 2/20 0.49
IDO1 P14902 2/20 0.49
LRRK2 Q5S007 1/20 0.47
NLRP3 Q96P20 1/20 0.45
LMNA P02545 4/20 0.43
HPGD P15428 3/20 0.43
ALDH1A1 P00352 2/20 0.43
L3MBTL1 Q9Y468 2/20 0.43
NPSR1 Q6W5P4 1/20 0.43
MEN1 O00255 2/20 0.43
KMT2A Q03164 2/20 0.43
NPC1 O15118 2/20 0.40
RAB9A P51151 2/20 0.40
MAPT P10636 2/20 0.40
BAZ1A Q9NRL2 1/20 0.40
UBE2M P61081 1/20 0.40
DCUN1D1 Q96GG9 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
POLB P06746 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7968253 0.79 MAPT (0.54) MTORIDO1LMNAALDH1A1L3MBTL1
SCHEMBL7979826 0.72 LMNA (0.53) IDO1LMNAALDH1A1L3MBTL1NPSR1
SCHEMBL255088 0.72 MTOR (1.00) MTORMAOBMEN1KMT2ANPC1
SCHEMBL7785354 0.68 IDO1 (0.53) MAOBIDO1ALDH1A1NPSR1KMT2A
SCHEMBL4317540 0.68 MEN1 (0.49) IDO1LMNAALDH1A1L3MBTL1NPSR1
SCHEMBL30753398 0.68 MEN1 (0.60) IDO1HPGDALDH1A1NPSR1MEN1
SCHEMBL173527 0.68 MEN1 (0.60) IDO1HPGDALDH1A1NPSR1MEN1
SCHEMBL10220026 0.67 MTOR (0.80) MTORMAOBLMNAALDH1A1NPSR1
Hydrochloric Acid SCHEMBL4425282 0.67 LMNA (0.48) IDO1LMNAALDH1A1L3MBTL1NPSR1
SCHEMBL12337052 0.67 MAPT (0.58) IDO1LMNAALDH1A1L3MBTL1NPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240002350-A1 PROTEIN AND LIPID THERAPEUTIC TARGETS UNIV PITTSBURGH COMMONWEALTH SYS HIGHER EDUCATION (US) 2024-01-04 US claimed
WO-2022108980-A1 PROTEIN AND LIPID THERAPEUTIC TARGETS UNIVERSITY OF PITTSBURGH-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) 2022-05-27 WO claimed
US-20240002350-A1 PROTEIN AND LIPID THERAPEUTIC TARGETS UNIV PITTSBURGH COMMONWEALTH SYS HIGHER EDUCATION (US) 2024-01-04 US disclosed
WO-2022108980-A1 PROTEIN AND LIPID THERAPEUTIC TARGETS UNIVERSITY OF PITTSBURGH-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) 2022-05-27 WO disclosed
WO-2022108980-A1 PROTEIN AND LIPID THERAPEUTIC TARGETS UNIVERSITY OF PITTSBURGH-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) 2022-05-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240002350-A1 PROTEIN AND LIPID THERAPEUTIC TARGETS PEBP1, ALOX15, ALOX15B MTOR 2005/4885MAOB 1222/4885IDO1 3318/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.